Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | METAP1 | P53582 | 1/20 | 0.31 |
| ▸ | ACLY | P53396 | 1/20 | 0.31 |
| ▸ | CEL | P19835 | 2/20 | 0.31 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2151198 | 0.98 | CYP1A2 (0.39) | CYP1A2SIGMAR1ALDH1A1ATMHPGD | |
| SCHEMBL17645782 | 0.95 | CYP1A2 (0.31) | CYP1A2ALDH1A1ATM | |
| SCHEMBL17803560 | 0.90 | — | — | |
| SCHEMBL6958222 | 0.84 | CYP1A2 (0.46) | CYP1A2SIGMAR1HPGDCELEPHX1 | |
| SCHEMBL4312611 | 0.79 | — | — | |
| SCHEMBL6581204 | 0.75 | SIGMAR1 (0.38) | CYP1A2SIGMAR1ALDH1A1ATMMETAP1 | |
| SCHEMBL19488904 | 0.75 | CYP1A2 (0.36) | CYP1A2SIGMAR1ALDH1A1ATMHPGD | |
| SCHEMBL3048106 | 0.75 | CYP1A2 (0.36) | CYP1A2SIGMAR1ALDH1A1ATMHPGD | |
| SCHEMBL4072061 | 0.75 | ALDH1A1 (0.37) | CYP1A2SIGMAR1ALDH1A1ATMHPGD | |
| SCHEMBL3048108 | 0.75 | CYP1A2 (0.41) | CYP1A2SIGMAR1ALDH1A1ATMHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1191026-B1 | New pyridazine endothelin antagonists | PFIZER LTD (GB) | 2004-05-19 | — | — | EP | disclosed |
| US-6670362-B2 | Treatment of restenosis, acute or chronic renal failure, pulmonary hypertension, systemic hypertension, benign prostatic hyperplasia, male erectile dysfunction, prostate cancer, metastatic bone cancer, angina, atherosclerosis | PFIZER INC. | 2003-12-30 | — | — | US | disclosed |
| US-20020061889-A1 | New pyridazine endothelin antagonists | PFIZER INC. | 2002-05-23 | — | — | US | disclosed |
| EP-1191026-A1 | New pyridazine endothelin antagonists | Pfizer Limited (GB) | 2002-03-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020061889-A1 | New pyridazine endothelin antagonists | EDNRB, EDNRA, ECE1 | CYP1A2 604/4885SIGMAR1 765/4885ALDH1A1 2724/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.